Nilotinib 300mg BID as frontline treatment of CML:Prospective analysis of the Xpert BCR-ABL Monitor system and significance of 3-month molecular response
| Data(s) |
01/12/2013
|
|---|---|
| Resumo |
Sixty patients with early chronic phase CML (ECPCML) received Nilotinib on a phase II study which included a comparison of the Xpert BCR-ABL Monitor™ PCR system with standardized (IS) BCR-ABL1 real-time quantitative PCR (RQ-PCR). 88% patients achieved MMR with 45% achieving MR4.5. At 3 months BCR-ABL1/ABL1 IS >1% and |
| Identificador | |
| Idioma(s) |
eng |
| Direitos |
info:eu-repo/semantics/restrictedAccess |
| Fonte |
O'Dwyer , M E , Swords , R , Nagler , A , McMullin , M F , le Coutre , P D , Langabeer , S E , Alvarez-Iglesias , A , Fan , H , Woodman , R C , Giles , F J & Conneally , E 2013 , ' Nilotinib 300mg BID as frontline treatment of CML : Prospective analysis of the Xpert BCR-ABL Monitor system and significance of 3-month molecular response ' Leukemia Research , vol 38 , no. 3 , pp. 310-315 . DOI: 10.1016/j.leukres.2013.11.016 |
| Palavras-Chave | #/dk/atira/pure/subjectarea/asjc/1300/1306 #Cancer Research #/dk/atira/pure/subjectarea/asjc/2700/2720 #Hematology #/dk/atira/pure/subjectarea/asjc/2700/2730 #Oncology |
| Tipo |
article |
